مشروع البحث:
Effects of COVID-19 on glycemic control in type 2 diabetes patients at the Medical preventive Hospital, Imitiga, Tripoli

dc.contributor.advisorعلي عثمان العيكي
dc.date.accessioned2024-11-25T11:44:05Z
dc.date.available2024-11-25T11:44:05Z
dc.description1.1.4.1 SARS-CoV-2 Variants of Concern (VOCs) Alpha (B.1.1.7 lineage): B.1.1.7 lineage, commonly known as Alpha variant or GRY(formerly GR/501Y.V1), a novel SARS-CoV-2 variation of concern was discovered in the UK in late December 2020, based on whole-genome sequencing of samples from patients who tested positive for SARS-CoV-2 (31). It was found in a commonly used commercial test defined by the lack of the S gene (S-gene target failure, SGTF) PCR samples, in addition to being detected by genome sequencing. The viral genome of the B.1.1.7 variant has 17 mutations. The spike (S) protein has about eight mutations. The spike protein has a higher affinity for ACE 2 receptors, which improves viral attachment and subsequent penetration into host cells (55)(56).
dc.description.abstractAs previously stated, SARS-CoV-2 is susceptible to genetic evolution, resulting in many variations with distinct features from the original strains. Periodic genomic sequencing of viral samples is critical, especially in the event of a global pandemic with increased transmissibility but not the ability to cause severe illness, where were multiple SARS-CoV-2 variants have been identified, with a few being classified as variants of concern (VOCs) due to their potential to increase transmissibility or virulence, reduce neutralization by antibodies obtained through natural infection or vaccination, evade detection, or reduce therapeutic or vaccination effectiveness. With the introduction of many variations, the CDC and WHO have developed their own categorization system for separating developing SARS-CoV-2 variants into variants of concern (VOCs) and variants of interest (VOIs) (30).
dc.identifier2337
dc.identifier.urihttps://dspace.academy.edu.ly/handle/123456789/331
dc.subjectEffects of COVID-19 on glycemic control in type 2 diabetes patients at the Medical preventive Hospital, Imitiga, Tripoli
dc.titleEffects of COVID-19 on glycemic control in type 2 diabetes patients at the Medical preventive Hospital, Imitiga, Tripoli
dspace.entity.typeProject
project.endDate2023
project.funder.nameالطب الحيوي
project.investigatorفاطمة غيت محمد علي
project.startDate2022
الملفات
الحزمة الأصلية
يظهر اﻵن 1 - 3 من 3
لا توجد صورة مصغرة متاحة
اﻻسم:
1st paper.pdf
الحجم:
1.02 MB
التنسيق:
Adobe Portable Document Format
لا توجد صورة مصغرة متاحة
اﻻسم:
contents.docx.pdf
الحجم:
2.26 MB
التنسيق:
Adobe Portable Document Format
لا توجد صورة مصغرة متاحة
اﻻسم:
CHAPTERS.pdf
الحجم:
2.26 MB
التنسيق:
Adobe Portable Document Format
حزمة الترخيص
يظهر اﻵن 1 - 1 من 1
لا توجد صورة مصغرة متاحة
اﻻسم:
license.txt
الحجم:
1.71 KB
التنسيق:
Item-specific license agreed to upon submission
الوصف: